Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
Edlund H, Bellanti F, Liu H, Vishwanathan K, Tomkinson H, Ware J, Sharma S, Buil-Bruna N. Edlund H, et al. Among authors: bellanti f. Br J Clin Pharmacol. 2022 Feb;88(2):846-852. doi: 10.1111/bcp.14988. Epub 2021 Aug 21. Br J Clin Pharmacol. 2022. PMID: 34265100 Free PMC article.
Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.
Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP). Bellanti F, et al. Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6. Br J Clin Pharmacol. 2017. PMID: 27641003 Free PMC article. Clinical Trial.
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A, Anderson K, Nelson C, Ni L, Chuang SM, Bellanti F, Chang P, Comisar C, Kearney BP, Bartok B, Mathias A. Meng A, et al. Among authors: bellanti f. Br J Clin Pharmacol. 2022 Jul;88(7):3211-3221. doi: 10.1111/bcp.15239. Epub 2022 Feb 14. Br J Clin Pharmacol. 2022. PMID: 35072287 Free PMC article. Clinical Trial.
Integration of PKPD relationships into benefit-risk analysis.
Bellanti F, van Wijk RC, Danhof M, Della Pasqua O. Bellanti F, et al. Br J Clin Pharmacol. 2015 Nov;80(5):979-91. doi: 10.1111/bcp.12674. Epub 2015 Jul 29. Br J Clin Pharmacol. 2015. PMID: 25940398 Free PMC article. Review.
127 results